Shares of FBT Up 21.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 12, 4:56PM CDT
SmarTrend identified an Uptrend for First Trust AMEX Biotechnology Index Fund (AMEX:FBT) on April 23rd, 2014 at $75.14. In approximately 5 months, First Trust AMEX Biotechnology Index Fund has returned 21.60% as of today's recent price of $91.37.
Ixonos Creates Future Look for Forbidden Technologies Forscene Cloud-Based Video Editing Platform
M2 - Fri Sep 12, 9:24AM CDT
LONDON, UK / SAN FRANCISCO, USA / HELSINKI, FINLAND - Creative technology company Ixonos today announced that it has provided design and technology services for Forbidden Technologies (AIM: FBT), the developer of the market-leading cloud-based video platform, Forscene. Ixonos has provided key design implementations for the revised interface for the Forscene platform, which will be shown at IBC 2014, in Amsterdam, from September 12-16, in beta phase at the Forbidden Technologies stand #8.B38e in Hall 8 of the RAI Convention Centre.
First Trust AMEX Biotechnology Index Fund Has Returned 20.1% Since SmarTrend Recommendation (FBT)
Comtex SmarTrend(R) - Fri Sep 05, 11:09AM CDT
SmarTrend identified an Uptrend for First Trust AMEX Biotechnology Index Fund (AMEX:FBT) on April 23rd, 2014 at $75.14. In approximately 5 months, First Trust AMEX Biotechnology Index Fund has returned 20.08% as of today's recent price of $90.23.
Top Performing Sector ETFs of August - ETF News And Commentary
Sweta Killa - ZACKS - Fri Aug 29, 1:00PM CDT
Few sector ETFs have performed exceptionally well this month and are leading the market higher.
Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
Biotech ETFs Surge on InterMune-Roche Deal - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Tue Aug 26, 12:00PM CDT
The news of InterMune's acquisition by Roche has led to a rally in the biotech ETFs space.
First Trust AMEX Biotechnology Index Fund Shares Up 15.9% Since SmarTrend's Buy Recommendation (FBT)
Comtex SmarTrend(R) - Fri Aug 22, 9:44AM CDT
SmarTrend identified an Uptrend for First Trust AMEX Biotechnology Index Fund (AMEX:FBT) on April 23rd, 2014 at $75.14. In approximately 4 months, First Trust AMEX Biotechnology Index Fund has returned 15.94% as of today's recent price of $87.12.
First Trust AMEX Biotechnology Index Fund Up 14.5% Since SmarTrend Uptrend Call (FBT)
Comtex SmarTrend(R) - Thu Aug 14, 5:03PM CDT
SmarTrend identified an Uptrend for First Trust AMEX Biotechnology Index Fund (AMEX:FBT) on April 23rd, 2014 at $75.14. In approximately 4 months, First Trust AMEX Biotechnology Index Fund has returned 14.48% as of today's recent price of $86.02.
Uptrend Call Working As First Trust AMEX Biotechnology Index Fund Stock Rises 10.1% (FBT)
Comtex SmarTrend(R) - Thu Aug 07, 11:27AM CDT
SmarTrend identified an Uptrend for First Trust AMEX Biotechnology Index Fund (AMEX:FBT) on April 23rd, 2014 at $75.14. In approximately 4 months, First Trust AMEX Biotechnology Index Fund has returned 10.07% as of today's recent price of $82.71.
3 American ETFs That Saw Fireworks to Start 2014 - ETF News And Commentary
Eric Dutram - ZACKS - Thu Jul 03, 11:00AM CDT
Several US focused ETFs put up gains of at least 20 percent to start 2014.
The Zacks Analyst Blog Highlights:Vertex Pharmaceuticals, Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, First Trust NYSE Arca Biotechnology Index Fund, PowerShares Dynamic Biotechnology & Genome Portfolio and SPDR S&P Biotech ETF
PR Newswire - Thu Jun 26, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Vertex Pharmaceuticals (Nasdaq:VRTX-Free Report), Market Vectors Biotech ETF (AMEX:BBH-Free Report), iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), First Trust NYSE Arca Biotechnology Index Fund (AMEX:FBT-Free Report), PowerShares Dynamic Biotechnology & Genome Portfolio (AMEX
Vertex Pharma Pushes Biotech ETFs Higher - ETF News And Commentary
Sweta Killa - ZACKS - Wed Jun 25, 1:00PM CDT
The positive trial results of a cystic fibrosis send Vertex Pharmaceuticals and these biotech ETFs higher on Tuesday trading session.
How Will Biotechnology ETFs Finish Out the Year? - ETF News And Commentary
Zacks Equity Research - ZACKS - Tue Jun 24, 9:00AM CDT
Which trend will prevail in the volatile biotechnology ETF space.